GenFleet Therapeutics (Shanghai) Inc. (GENFLEET-B) disclosed that it repurchased 38,000 H shares on 13 October 2026 via on-market transactions at prices between HKD 26.92 and HKD 27.00, for a volume-weighted average of HKD 26.98 per share. The aggregate consideration was HKD 1.03 million.
Following the transaction, the company’s issued share capital (excluding treasury shares) decreased by 0.011 % to 350.47 million shares. Treasury shares rose to 1.16 million, leaving total issued shares unchanged at 351.63 million.
The buyback was executed under the mandate approved on 11 May 2026, which authorises the repurchase of up to 37.04 million shares. Cumulative repurchases under this mandate now total 1.16 million shares, equivalent to 0.313 % of the share count on the mandate date.
As prescribed by Hong Kong listing rules, GENFLEET-B is subject to a 30-day moratorium on issuing new shares or selling treasury shares, lasting until 12 November 2026.